Jennifer E. Vaughn
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
77
Citations
422
Est. group size
~4
Recurring co-author estimate
Active years
17
Publishing since 2010
Jennifer E. Vaughn's work centers on clinical and translational research in blood cancers and related drug therapies, including chronic myeloid leukemia treatment comparisons, systemic mastocytosis drug trials, and the biological factors influencing side effects of cancer drugs (such as joint pain from aromatase inhibitors and how the body transports these drugs). Much of this research involves clinical trial results, cost-effectiveness analyses of cancer treatments, and studies of genetic factors affecting drug response and side effects.
Publication output was sporadic and low through 2017-2023 but increased sharply starting in 2024, with a large surge in 2025, suggesting a recent period of intensified research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Expanded Results From the Phase 2 Summit Trial: Bezuclastinib in Adults With Non-Advanced Systemic Mastocytosis
Journal of Allergy and Clinical Immunology · 2026
- Results in Subgroups with Unmet Need in the Summit Trial: Bezuclastinib in Adults with Non-Advanced Systemic Mastocytosis
Journal of Allergy and Clinical Immunology · 2026
- Financial Impact of Treatment Choice in Chronic Myeloid Leukemia: A Comparison of Later Generation TKIs versus Imatinib from Patient and Payer Perspectives
ClinicoEconomics and Outcomes Research · 2026
- OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
Cancer Research Communications · 2025
- Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Blood · 2025
- Treatment cost per AE symptom-free day of asciminib and second-generation tyrosine kinase inhibitors in newly diagnosed patients with chronic myeloid leukemia
Blood · 2025
- Figure S5 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025
- Figure 6 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025
- Figure S3 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025
- Supplementary documents from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025
- Table 3 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025
- Table 1 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025
- Table 2 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025
- Figure S6 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025
- Figure S2 from OATP1B-type Transport Function Is a Determinant of Aromatase Inhibitor–Associated Arthralgia Susceptibility
2025
- Blood×12
- Journal of Clinical Oncology×5
- Current Hematologic Malignancy Reports×2
- Journal of Allergy and Clinical Immunology×2
- Journal of the National Comprehensive Cancer Network×1
- Kara N. Corps
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Heather L. Walker
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Christopher C. Coss
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Hanieh Taheri
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- James P. Sluka
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile